Prevention of motion sickness with selegilinum hydrochloricum. 1989

G Bodó, and K Elkán, and G Bencze

Summarizing, it may be concluded that selegilinum hydrochloricum significantly prolongs the time before the development of nausea and vomiting provoked by vestibular stimulation. The drug controls, within a short period, the provoked discomfort, and restores normal condition rapidly. It prevents the changes in blood pressure, pulse rate, and cutaneous galvanic resistance following Coriolis stimulus. Due to these properties Jumex may be used for the prevention, moderation of motion sickness, one of the widespread phenomena of our age, without decreasing working capacity.

UI MeSH Term Description Entries
D008297 Male Males
D009041 Motion Sickness Disorder caused by motion. It includes sea sickness, train sickness, roller coaster rides, rocking chair, hammock swing, car sickness, air sickness, or SPACE MOTION SICKNESS. Symptoms include nausea, vomiting and/or dizziness. Airsickness,Carsickness,Seasickness,Air Sickness,Car Sickness,Sea Sickness,Sickness, Air,Sickness, Car,Sickness, Motion,Sickness, Sea
D010627 Phenethylamines A group of compounds that are derivatives of beta- aminoethylbenzene which is structurally and pharmacologically related to amphetamine. (From Merck Index, 11th ed) Phenylethylamines
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012642 Selegiline A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl. Deprenalin,Deprenil,Deprenyl,E-250,Eldepryl,Emsam,Humex,Jumex,L-Deprenyl,Selegiline Hydrochloride,Selegiline Hydrochloride, (R)-Isomer,Selegiline Hydrochloride, (R,S)-Isomer,Selegiline Hydrochloride, (S)-Isomer,Selegiline, (R)-Isomer,Selegiline, (R,S)-Isomer,Selegiline, (S)-Isomer,Selegyline,Yumex,Zelapar,E 250,E250

Related Publications

G Bodó, and K Elkán, and G Bencze
August 1967, British medical journal,
G Bodó, and K Elkán, and G Bencze
November 1959, Proceedings of the Royal Society of Medicine,
G Bodó, and K Elkán, and G Bencze
July 2014, American family physician,
G Bodó, and K Elkán, and G Bencze
July 2014, American family physician,
G Bodó, and K Elkán, and G Bencze
January 1974, Wiadomosci lekarskie (Warsaw, Poland : 1960),
G Bodó, and K Elkán, and G Bencze
April 1970, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
G Bodó, and K Elkán, and G Bencze
June 2003, The Medical journal of Australia,
G Bodó, and K Elkán, and G Bencze
September 1958, Klinicheskaia meditsina,
G Bodó, and K Elkán, and G Bencze
January 1982, Archiv fur Psychiatrie und Nervenkrankheiten,
G Bodó, and K Elkán, and G Bencze
August 1967, Current medicine and drugs,
Copied contents to your clipboard!